Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 7/20 | 0.69 |
| ▸ | FABP2 | P12104 | 2/20 | 0.69 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.69 |
| ▸ | PPARD | Q03181 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.60 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.60 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.60 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.60 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.60 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9416384 | 0.87 | PPARG (0.59) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| SCHEMBL28624789 | 0.86 | PPARA (0.68) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| SCHEMBL21991244 | 0.86 | NPC1 (0.55) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| Clofibric Acid SCHEMBL317991 | 0.85 | PPARA (0.96) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| SCHEMBL21992469 | 0.84 | PPARA (0.75) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| SCHEMBL3811479 | 0.84 | PPARA (0.81) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| SCHEMBL21991514 | 0.84 | L3MBTL1 (0.55) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| Clofibric Acid SCHEMBL102826 | 0.83 | PPARA (1.00) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| Clofibric Acid SCHEMBL2227936 | 0.83 | PPARA (1.00) | PPARAMAPTCYP1A2CYP3A4MEN1 | |
| SCHEMBL21991790 | 0.83 | CNR1 (0.73) | PPARAMAPTCYP1A2CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAPT 4264/4885CYP1A2 2919/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | PPARA 806/4885MAPT 4264/4885CYP1A2 2919/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAPT 4264/4885CYP1A2 2919/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAPT 4264/4885CYP1A2 2919/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAPT 4264/4885CYP1A2 2919/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MAPT 4264/4885CYP1A2 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.